SWORX Performance — Schwab Target 2055 Fund
Data updated: 2026-09-24
SWORX returned +10.22% year to date and +20.65% over one year to Jul 2026. Annualised returns are +16.00% over 3 years and +8.62% over 5 years. The fund beat its Target-Date category average: $100 invested three years ago grew to $156, against $146 for the category, and to $121 over one year, against $116. Volatility over the past three years was 12.13% a year. In the 12 months to Jul 2026 the fund lost a net $66.7M, and assets reached $227.40M.
SWORX Growth of $100
What $100 invested in Schwab Target 2055 Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Target-Date category average over the same months.
| Period | SWORX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $121 | $116 |
| 3 years (Aug 2023 – Jul 2026) | $156 | $146 |
| 5 years (Aug 2021 – Jul 2026) | $151 | $142 |
| Since data start (Aug 2019 – Jul 2026) | $214 | $186 |
SWORX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +10.22% |
| 1 year | +20.65% |
| 3 years (annualised) | +16.00% |
| 5 years (annualised) | +8.62% |
SWORX Annual Returns
Calendar-year total returns of Schwab Target 2055 Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +10.22% |
| 2025 | +20.10% |
| 2024 | +14.07% |
| 2023 | +20.74% |
| 2022 | −20.01% |
| 2021 | +18.23% |
| 2020 | +15.31% |
| 2019 (Aug–Dec) | +7.57% |
SWORX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.2% | +2.1% | −6.5% | +8.5% | +3.9% | +0.1% | −0.9% | — | — | — | — | — |
| 2025 | +3.3% | −0.5% | −3.5% | +0.7% | +5.0% | +4.3% | +0.4% | +3.2% | +3.1% | +1.7% | +0.4% | +0.8% |
| 2024 | −0.1% | +4.3% | +3.0% | −3.9% | +4.5% | +1.4% | +2.1% | +2.3% | +1.6% | −2.3% | +4.0% | −3.2% |
| 2023 | +7.8% | −2.9% | +2.2% | +1.1% | −1.0% | +5.7% | +3.2% | −2.6% | −4.4% | −3.2% | +8.8% | +5.5% |
| 2022 | −5.4% | −3.2% | +1.4% | −7.8% | +0.4% | −8.3% | +7.1% | −4.3% | −9.5% | +6.1% | +7.8% | −4.2% |
| 2021 | −0.2% | +2.9% | +2.4% | +4.6% | +1.4% | +1.4% | +0.9% | +2.4% | −4.2% | +4.5% | −2.5% | +3.9% |
| 2020 | −1.3% | −6.9% | −14.9% | +11.0% | +5.1% | +3.2% | +4.9% | +5.3% | −2.7% | −1.9% | +11.1% | +4.7% |
| 2019 | — | — | — | — | — | — | — | −2.2% | +1.5% | +2.5% | +2.6% | +3.1% |
SWORX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 12.13%
- 3-year Sharpe ratio: 0.95 (vs 4.5% risk-free rate)
- Best month: +8.79% (Nov 2023)
- Worst month: −6.49% (Mar 2026)
SWORX Fund Flows
Monthly money in and out of Schwab Target 2055 Fund, from SEC Form N-PORT.
- 12-month net flow: −$66.7M
- 12-month gross sales (incl. reinvestments): $56.8M
- Sales ÷ redemptions: 0.46×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $7.0M | $1.7M | $5.3M |
| Jun 2026 | $1.7M | $2.1M | −$364K |
| May 2026 | $2.3M | $94.6M | −$92.2M |
| Apr 2026 | $3.3M | $2.5M | $759K |
| Mar 2026 | $3.5M | $2.2M | $1.3M |
| Feb 2026 | $7.9M | $3.0M | $4.9M |
| Jan 2026 | $4.6M | $3.1M | $1.5M |
| Dec 2025 | $14.4M | $1.6M | $12.8M |
| Nov 2025 | $2.4M | $2.4M | −$35K |
| Oct 2025 | $3.6M | $2.9M | $644K |
| Sep 2025 | $3.5M | $5.2M | −$1.7M |
| Aug 2025 | $2.6M | $2.2M | $394K |
SWORX Assets Under Management
Net assets of Schwab Target 2055 Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $227.40M |
| 2026-04-30 | $306.11M |
| 2026-01-31 | $288.42M |
| 2025-10-31 | $273.69M |
| 2025-07-31 | $253.72M |
| 2025-04-30 | $225.83M |
| 2025-01-31 | $232.01M |
| 2024-10-31 | $220.31M |
| 2024-07-31 | $217.47M |
| 2024-04-30 | $198.21M |
| 2024-01-31 | $189.15M |
| 2023-10-31 | $161.69M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.